T3 is essential for normal development and metabolism. Its action is mediated by its binding to the nuclear receptors TRa1 and TRb1/2, which are ligand-dependent transcription factors encoded by the THRA and THRB genes. THRA germline mutations cause a rare genetic disease called RTHa, first reported in 2012 [1, 2] . The variety of symptoms, their variable severity, and the absence of reliable biochemical markers make the diagnosis difficult [3, 4] . Only 20 missense and frameshift mutations have been reported to date, in 31 patients (Table 1) . From this small group of patients and analysis of animal models, researchers have determined the disease severity correlates with the inability of the receptor to release transcription corepressors in the presence of T3 [13] . This can result from either a decrease in the affinity of TRa1 for T3 or from an alteration of its C-terminal helix, which normally recruits transcription coactivators upon T3 binding, releasing corepressors.
Case Report
We report on a patient with RTHa in China. The patient is the only child of healthy, unrelated parents. This boy was born at full term by vaginal delivery. His birth weight was 4 kg. His developmental milestones were delayed: He walked at 18 months and knew only two words at age 2 years ("mama" and "baba"). Poor coordination and clumsiness were noted. At 2 years old, he underwent the Denver Developmental Screening Test, which result of which was abnormal. The child had chronic constipation.
On examination at age 2 years, the patient's height was 80 cm (reference range, 82.1 to 95.3 cm). At 3 years, his skeletal growth remained retarded (83.5 cm; reference range, 89.7 to 104.1 cm). He was disproportionately short, with a short arm span (78 cm). The patient's heart rate was low (85/min; reference range, 100 to 120/min). His skin was thick without skin tags. The face and nasal bridge were broad, but there was no macroglossia.
The patient underwent multiple thyroid function tests (Table 2) . Although T4 and TSH levels remained within reference ranges, his T3 level was slightly elevated. This resulted in a marked reduction of the T4-to-T3 ratio. Consistent with the patient's slow body growth, his IGF-1 level was low. Muscle creatine kinase levels were also elevated, possibly because of the elevated T3 level. The patient's Hb level was low, indicative of mild anemia. Results of the screening tests for metabolic defects, including analyses of blood and urine amino acids and urinary organic acid were normal. Routine karyotyping (G-bands) showed 46,XY.
We evaluated the thyroid gland function by measuring serum thyroglobulin level, which was slightly elevated. We searched for antibodies directed against thyroid peroxidase, or thyroglobulin, which were absent at this early stage. Observations on ultrasonic cardiogram and thyroid pelvic ultrasound were normal. Head and pituitary MRI appeared normal. Overall, the function of the pituitary-thyroid gland axis appeared close to normal, in contrast with the severe symptoms evocative of hypothyroidism. Radiographic studies showed a normal morphology of the vertebral column and no sign of hip dislocation. Wormian bones were absent. At 3 years old, the patient's head circumference was within normal range (51 cm; reference range, 45.7 to 52.2 cm). After obtaining the patient's informed consent (2016034), we performed DNA sequencing using target region sequencing and Sanger sequencing. This revealed that the patient was heterozygous for a THRA mutation (c.1183G.T,p.E395X), which was absent in his parents.
The initial dose of 25 mg/d levothyroxine was ordered. The child was irregularly taking medication. Approximately 6 months later, his motor coordination remained poor and clumsiness was visible, but his parents rejected further examination. After then, he was lost to follow-up. 
Discussion
The E395X mutation eliminates the C-terminal helix of TRa1 and, thus, is expected to display consequences similar to that of C392X, F397fs406X, and E403X mutations, which exert a strong dominant-negative influence in heterozygous cells. Our observations confirm that, for this type of mutation, levothyroxine-T4 treatment provides little benefit, and the manifestations of RTHa are severe. Our findings also indicate the variability in RTHa manifestations; RTHa remains difficult to recognize even in its severe form. In the patient described here, constipation, small stature, mild anemia, and mental retardation were typical traits of the disease that were reported also for the aforementioned similar cases. The T4 and TSH levels also remained within normal range, and T3 was slightly elevated, which fits the general trend of observing a low T4-to-T3 ratio in these patients. The moderate decrease in IGF-1 and the increase in muscle creatine kinase level are also consistent with previous case reports [3] . By contrast, the slight elevation in thyroglobulin level was not typical of the disease. Perhaps more importantly, the patient's head circumference was normal, whereas it is elevated in all patients with mutations altering the C-terminal helix 12 of the receptor (Table 1) . Therefore, our data confirm that RTHa diagnosis cannot rely on a single clinical trait and that the manifestation of the disease varies even for patients with seemingly equivalent mutations.
